46P - Activity of IAP antagonist Debio 1143 as a monotherapy and in combination with standard of care agents in models of human lung cancer of different h...
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Basic Science
Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
N. Wiedemann1, C.G. Langdon2, M.A. Held2, J.T. Platt2, C. Zanna3, M. Sorensen4, S. Wang5, M.W. Bosenberg2, D.F. Stern2, G. Vuagniaux1
Drug resistance is a major problem in cancer therapy and response to therapy varies between histotypes and within the same histotype. Resistance may be overcome by the combination of drugs simultaneously targeting multiple critical nodes of the signalling networks controlling growth and survival of cancer cells. The members of the Inhibitor of apoptosis protein (IAP) family are frequently overexpressed in most cancer types contributing to tumour cell survival and resistance to cancer therapy. The oral monovalent IAP inhibitor Debio 1143/AT-406 is currently in clinical development for cancer treatment. The aim of the study was to evaluate the activity of Debio 1143 as a single agent and in drug combinations in in vitro and in vivo lung cancer models of different histotypes.